Text Size

Serotonin/Dopamine Antagonism of Cocaine Effect: 2 - 2

This study has been terminated.
Sponsor:
Collaborator:
VA Boston Healthcare System
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00000310
First received: September 20, 1999
Last updated: August 16, 2005
Last verified: January 1996
History of Changes
  Purpose

The purpose of this study is to evaluate use of risperidone with cocaine abusers. Study measures incorporate an appropriate integration of behavioral and neurobiological indices.


Condition Intervention Phase
Cocaine-Related Disorders
 Drug: Risperidone
 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Serotonin/Dopamine Antagonism of Cocaine Effect

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Urine toxicology for cocaine
  • Analog mood scales
  • POMS
  • EPS sx

Estimated Enrollment: 0
Study Start Date: January 1996
Detailed Description:

Risperidone in low doses is compared with placebo in a 6-week randomized trial. Subjects also receive supportive counseling. Outcome measure include rating of behavior, mood, drug abuse, global function, and urine toxicology.

  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Cocaine abuse or dependence

Exclusion Criteria:

Dependence on other drugs. Major psychiatric illness

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000310

Locations
United States, Rhode Island
Brown University School of Medicine
Providence, Rhode Island, United States, 2906
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
VA Boston Healthcare System
Investigators
Principal Investigator: Lawrence Price, M.D. Brown University
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00000310     History of Changes
Other Study ID Numbers: NIDA-09330-2, R01-09330-2
Study First Received: September 20, 1999
Last Updated: August 16, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Mental Disorders
Dopamine
Risperidone
Serotonin
Cardiotonic Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
 Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Protective Agents
Serotonin Receptor Agonists
Serotonin Agents
Serotonin Antagonists
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Central Nervous System Agents
Psychotropic Drugs
Dopamine Antagonists

ClinicalTrials.gov processed this record on May 23, 2013